[
    {
        "type": "text",
        "text": "探究DEN诱导大鼠肝癌-炎癌模型中尿液蛋 白质组的变化 ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "王云龙」 高友鹤\\*（北京师范大学基因工程药物及生物技术北京市重点实验室 北京100871)",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "摘要: ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "[目的]通过DEN诱导的肝癌-炎癌模型，观察疾病不同阶段尿液蛋白质组动态变化过程。[方法]本研究腹腔注射DEN构建大鼠肝癌-炎癌模型，每周收集尿液，通过液相色谱联用质谱（LC-MS/MS）鉴定差异蛋白，使用IPA软件对差异蛋白进行生物学通路的分析，观察大鼠肝癌-炎癌模型中疾病不同阶段尿蛋白变化情况。  \n[结果]15只实验大鼠通过DEN诱导，构建了从肝炎-肝硬化-肝癌疾病模型的不同时期，并且每只大鼠由于个体差异出现了疾病进展快慢不同的现象。每只大鼠在不同疾病时间点都出现了较多的差异蛋白，不同大鼠的差异蛋白都富集到了相同的与肝脏损伤、炎症病变有关、与肿瘤的发生有关、与肿瘤潜在的治疗靶点有关的生物学通路。  \n[讨论]我们可以在肝癌-炎癌模型各阶段观察到尿液蛋白质组不同的变化，并且不同大鼠由于个体差异会出现疾病进展不同的现象，这提示我们之后需要更加注意检测的个体化、精准化。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：蛋白质组学；尿液；炎癌模型；肝癌",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "To explore the changes of the urinary proteome in DEN ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "induced liver cancer-inflammatory cancer model in rats ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Wang Yunlong‘ Gao Youhe\\* ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "(Gene Engineering Drug and Biotechnology Beijing Key Laboratory， Bei jing Normal ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "University，Beijing 100871，China) ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Abstract: ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "[Objective] Through the liver cancer-inflammatory cancer model induced by DEN, observe the dynamic change process of urine proteome at different stages of the disease. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "[Methods] In this study， a rat liver cancer-inflammatory cancer model was constructed by intraperitoneal injection of DEN， urine was collected weekly, and differential proteins were identified by liquid chromatography coupled with massspectrometry (LC-MS/MS)， and the biological pathways of differential proteins were analyzed using IPA software. To observe the changes in urine protein at different stages of the disease in the rat liver cancer-inflammatory cancer model. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "[Results] Fifteen experimental rats were induced by DEN to construct different stages of the hepatitis-cirrhosis-liver cancer disease model， and each rat had a different disease progression due to individual differences. Each rat has more differential proteins at different disease time points. The differential proteins of different rats are enriched in the same biological pathways related toliverinjury，inflammatorylesions，tumor occurrence, and potential therapeutic targets of the tumor. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "[Discussion] We can observe different changes of urine proteome in each stage of the liver cancer inflammatory cancer model， and different rats will have different disease progression due to individual differences， which suggests that we need to pay more attention to the individualization and accuracy of detection in the future. ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Keywords: Proteomics; Urine; Inflammatory cancer model;Liver cancer ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1引言",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "尿液是经血液过滤后形成的代谢废物，不受稳态机制的调节，能够富集机体为维持稳态而排出的各种变化。因此，尿液比血液更快、更灵敏地反映机体的变化，是挖掘早期疾病标志物的重要来源【，2】。在已有的研究中，肺纤维化【3】、星状细胞瘤[3]、胰腺癌[4]、膀胱癌[5等，都在尿液中发现了明显的差异蛋白。此外，尿液还具有无创、大量、连续收集的优点。因此，我们认为尿液是寻找生物标志物良好的生物学来源。使用动物模型，可以排除大量复杂因素的影响，将影响因素降到最低【。通过二乙基亚硝胺（DEN）诱导动物肝癌的发生，不同于以往的接种癌细胞的直接肝癌造模，炎癌模型模拟了人类从肝炎到肝硬化到肝癌的一步步进程，所以对于寻找人的肝癌早期标志物具有更加重要的实用意义。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "肝癌是非常常见的一种恶性肿瘤，其发病过程隐匿，病程时间短，发病率和死亡率却相对较高【】。在世界各国，肝癌均有发生，每年发病人数可达62.6万，死亡人数高达58.9万，是居全球第六位的常见肿瘤，并且在肿瘤死亡率中高居第三【8】。这说明了肝癌严重威胁着人类的健康和生命。我国是肝癌的高发病率国家之一，每年大约有10万余人死于原发性肝癌。全球 $8 0 \\%$ 的肝癌的发生，与感染引起的隐匿性肝炎及慢性病毒性肝炎，由此导致的肝脏炎性反应、肝纤维化及肝脏再生结节直接相关9。因此，早诊断、早治疗，对提高肝癌患者的生存至关重要。作为死亡率排名第三的癌症，由于目前尚没有有效的治疗措施，如何有效的预防肝癌的发生成了现在的一大难题。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "二乙基亚硝胺作为一种亚硝胺类，不仅是一种强化学致癌物，而且是生活中非常容易见到的食品污染物之一，食物、化妆品、啤酒、香烟中都含有亚硝胺。我们通过二乙基亚硝胺诱导肝癌模型的方式，可以确定动物肝癌以及癌前病变各个阶段的发病时间，是一种可靠的诱癌生物模型。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "本研究中，我们构建大鼠的肝癌-炎癌模型，每周收集尿液。并分别在不同时间节点进行取血、取组织，分别通过血液的生化指标和肝脏组织的HE切片来确定大鼠的病理进程。将收集到的尿液进行质谱分析，探究病情进展过程中尿液蛋白质组的变化以及相关生物学通路的变化，为肝癌的临床诊断乃至治疗靶点的寻找提供线索和依据。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2材料与方法",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2.1实验动物及模型构建 ",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "20只 $1 8 0 \\mathrm { g }$ 的雄性Wistar大鼠购自北京维通利华实验动物技术有限公司，按照 $5 0 \\mathrm { m g / k g }$ 的剂量每周对大鼠进行二乙基亚硝胺（DEN）腹腔注射，期间按照12小时正常光暗循环、温度为 $( 2 2 ^ { \\circ } \\mathrm { C } \\pm 1 ^ { \\circ } \\mathrm { C } )$ 、湿度为 $( 6 5 \\% - 7 0 \\% )$ 的标准条件进行饲养。每周进行一次尿液收集，在注射前（第0周）和注射后第4、12、16、18 周对大鼠进行取血肝功检测和取肝脏组织HE切片判断模型进展情况。所有实验操作符合动物伦理审查标准。动物许可证为SCXK（京）2016-0006。所有实验均经北京协和医学院基础医学研究所机构动物护理使用与福利委员会批准（动物福利保障编号：ACUC-A02-2014-007)",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2.2血生化检测 ",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "为方便判断大鼠肝癌-炎癌模型的进展情况以及炎癌模型各个阶段的血液变化情况，我们分别在二乙基亚硝胺腹腔注射之前（第0周）和注射后第4周、第12周、第16周、第18周，用 $2 \\%$ 的戊巴比妥钠按照 $0 . 2 \\mathrm { m l / 1 0 0 g }$ 的剂量腹腔注射麻醉大鼠，腹主动脉取血2ml。全血按照 $3 0 0 0 \\mathrm { r p m }$ ，10min， $\\mathrm { 4 ^ { \\circ } C }$ 的条件离心取血清。测定血清中谷丙转氨酶（ALT）、谷草转氨酶（AST）、碱性磷酸酶（ALP）、总蛋白（TP）、白蛋白（ALB）的变化情况。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "2.3组织病理切片",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "对腹主动脉取血之后的wistar大鼠进行心脏灌注处理。从左心尖部位进针到主动脉，快速灌注生理盐水，同时在右心耳处剪一个小口，大概灌注生理盐水 $6 0 \\mathrm { m l }$ 之后，流出液体变为无色，开始改换 $4 \\%$ 多聚甲醛。对灌注完成的大鼠，取肝脏观察肝脏大体情况。之后，取肝脏组织进行 HE 切片，通过Image Scope软件观察病理切片，判断大鼠肝癌-炎癌模型的病情进展情况。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "2.4尿液收集及样品处理",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "(1) 尿液收集",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "我们每周对大鼠进行二乙基亚硝胺腹腔注射和尿液收集，为尽量避免药物本身对于尿蛋白的影响。我们在每次腹腔注射6天以后，下一次腹腔注射之前，收集该次的尿液。每只大鼠在代谢笼中过夜收集尿液10小时，期间不提供水和食物。第二天早上将收集到的尿液立即放置于 $- 8 0 ^ { \\circ } \\mathrm { C }$ 条件下进行保存，等待后续实验。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "(2） 尿蛋白提取和酶切",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "尿蛋白提取：尿液按照 $1 2 0 0 0 \\mathrm { g }$ ，40min， $\\mathrm { 4 ^ { \\circ } C }$ 的条件离心取上清；将上清液每管 $5 0 0 \\mathrm { u l }$ 转移到新的EP管里，按照上清：乙醇 $\\mathrel { \\mathop = } 1$ ：3的比例加入预冷乙醇，搅拌均匀；在 $- 2 0 ^ { \\circ } \\mathrm { C }$ 条件下过夜 $\\mathrm { 1 2 h }$ ；第二天将溶液混匀，按照 $1 2 0 0 0 \\mathrm { g }$ ，30min， $\\mathrm { 4 ^ { \\circ } C }$ 条件离心弃上清、留沉淀，倒扣滤纸，吹风机冷风吹干；加入裂解液37.5ul,用枪头吹匀直到无沉淀为止，按照 $1 2 0 0 0 \\mathrm { g }$ ，30 min， $\\mathrm { 4 ^ { \\circ } C }$ 条件离心，取上清液，放入新EP管中分装、 $- 8 0 ^ { \\circ } \\mathrm { C }$ 条件保存。复溶后，采用Bradford 法测定蛋白质浓度。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "尿蛋白酶切：使用FASP方法进行尿蛋白酶解【10】。100ug尿蛋白加入到 $1 0 \\mathrm { k D }$ 超滤管（Pall，Port Washington，NY，USA）的滤膜上，使用UA溶液（8mol/L尿素，0.1mol/L Tris-HCl,pH8.5）和25mmol/L NH4HCO3溶液分别洗涤两次，按照胰酶：蛋白为1：50的比例加入胰蛋白酶（TrypsinGold,Promega，Fitchburg，WI,USA）进行消化， $3 7 ^ { \\circ } \\mathrm { C }$ 水浴过夜。过夜后离心收集多肽通过HLB固相萃取柱（Waters,Milford,MA）进行除盐处理，用真空干燥抽干，存入-$8 0 ^ { \\circ } \\mathrm { C }$ 保存。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "(3） LC-MS/MS串联质谱分析 ",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "酶切后的样品 $0 . 1 \\%$ 甲酸水复溶，并稀释到 $0 . 5 \\mu \\mathrm { ~ g / ~ \\mu ~ L ~ }$ ，取每个样品制备混合多肽样，使用高pH反相肽段分离试剂盒(Thermo Fisher Scientific)进行分离。将混合多肽样品加于色谱柱上，用乙腈浓度梯度递增的溶液进行洗脱，通过离心收集十份流出液，使用真空干燥仪抽干后用 $0 . 1 \\%$ 甲酸水复溶。使用iRT合成多肽（Biognosis 公司），以10：1的体积比例加入到十个组分和每个样品中。使用 EASY-nLC 1200 超高效液相色谱串联Orbitrap Fusion Lumos 高分辨质谱仪对10个分级组分进行数据采集。将溶于 $0 . 1 \\%$ 甲酸水中的肽段装载至预柱（75μm $\\times 2 \\mathrm { c m }$ ，3μm，C18，100A°），将洗脱液装载至反相分析柱0 $\\langle 5 0 \\mu \\mathrm { m } \\times 2 5 0 \\mathrm { m m }$ ， $2 \\mu \\mathrm { m }$ ，C18，100A°），洗脱梯度 $4 \\% - 3 5 \\%$ 流动相B（ $8 0 \\%$ 乙腈$+ 0 . \\ 1 \\%$ 甲酸 $+ 2 0 \\%$ 水，流速为300nL/min），90min。为实现全自动、灵敏的信号处理，在所有样品中使用校准试剂盒（iRTkit,Biognosys,Switzerland），浓度为 $1 { : } 2 0 \\mathrm { v } / \\mathrm { v }$ 。以DDA-MS 模式分析10个组分，参数设置如下：喷雾电压$2 . 4 \\mathrm { k V }$ ，Orbitrap的一级分辨率为60000、扫描范围为 $3 5 0 \\mathrm { - } 1 5 5 0 \\mathrm { m / z }$ ，二级扫描范围为 $2 0 0 { - } 2 0 0 0 \\mathrm { m / z }$ ，分辨率为30000，筛选窗口为2Da，碰撞能量为 $3 0 \\%$ HCD）。AGC目标为5e4，最大进样时间为 $3 0 \\mathrm { { m s } }$ 。raw 文件通过PD（ProteomeDiscoverer 2.1，Thermo Fisher Scientific 公司）软件建库和分析。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "(4） 质谱数据处理",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "将PD搜库结果用于建立DIA采集方法，根据 $\\mathrm { m / z }$ 分布密度计算窗口宽度和数量。将单个多肽样品进行DIA模式采集质谱数据。使用 Spectronaut X 软件对质谱数据进行处理和分析。导入每个样本DIA采集的raw文件进行搜库。高度可信蛋白标准为肽段qvalue<0.01，采用二级肽段所有碎片离子峰面积进行蛋白定量。",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "(5） 统计学分析 ",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "对质谱鉴定结果进行缺失值填充（KNN方法）【I】和CV值筛选（ $\\mathrm { C V } { \\langle 0 . 3 \\rangle }$ 【12】，每两组数据之间的比较采用独立样本t检验。为尽量减少大鼠生长发育本身对于尿蛋白的影响，我们采用相邻时间点的比较方法，即第4周与第0周比较、第8周与第4周比较、第12周与第8周比较、第16周与第12周比较、第18周与第16周比较的方法，筛选差异蛋白标准为：两组之间变化倍数 $\\mathrm { F C } \\geqslant 1 . 5$ 或$\\mathrm { F C } { \\leqslant } 0 . 6 7$ ， $\\mathrm { P } { < } 0 . \\ : 0 5$ 。",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "(6） 差异蛋白功能注释",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "将筛选到的差异蛋白用DAVID数据库（https://david.ncifcrf.gov/）【13】和IPA 软件(Ingenuity Systems，Mountain View，CA，USA)进行功能富集分析，均采用 $\\mathrm { P } { < } 0 . \\ : 0 5$ 的显著性阈值。",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "3实验结果",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "3.1大鼠体重变化",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "为大体确定模型进展情况，我们对15只肝癌-炎癌模型的wistar大鼠的体重状况每周进行了记录。大鼠的体重变化规律符合我们的预期。在腹腔注射大概8-9 周后，伴随着肝炎病情的加重，大鼠的体重在这一阶段出现了放缓的趋势。并且在腹腔注射大概15周左右，大鼠的体重变化出现了下降的趋势，这也跟之后我们的组织病理学结果相对应，在这一阶段，大鼠病情已经进展到了肝癌阶段。 (见图1)",
        "page_idx": 4
    },
    {
        "type": "image",
        "img_path": "images/2c77507c83baf17e19ab2661d771c366026e558aa532eb816830fa55127ee40d.jpg",
        "img_caption": [
            "Figure1．大鼠体重变化图"
        ],
        "img_footnote": [],
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "3.2血生化结果分析",
        "text_level": 1,
        "page_idx": 5
    },
    {
        "type": "text",
        "text": "血生化结果显示了肝癌-炎癌模型过程中，血液中肝功五项的变化结果。谷丙转氨酶（ALT）受肝细胞膜通透性的影响，一般与急性乙肝和慢性肝硬化有关。如图2a所示，谷丙转氨酶在12周后开始升高，这表明肝细胞受到了损害在12周后已经影响到血液。在图2b中，谷草转氨酶相对于谷丙转氨酶的升高有滞后性，它的升高提示肝细胞的损害已经发展到了细胞器水平，在16周后，血液中的谷草转氨酶水平升高。AST/ALT比值变化也与转氨酶一致，如图2c所示，在肝细胞开始损伤时，ALT会增加导致AST/ALT比值降低，当肝细胞线粒体受到伤害时，AST开始增加AST/ALT比值又会上升。在0-12周时，肝细胞开始损伤，16周后，肝细胞受到严重破坏。在图2d中我们可以发现，在肝癌-炎癌模型中，血液中最敏感的变化来自于碱性磷酸酶（ALP），其在第四周时就已有明显的升高，并且在疾病的进展过程中一直保持着较高的水平。肝脏作为主要的蛋白和白蛋白合成器官，但是在肝癌-炎癌模型中我们可以发现，当肝脏发生损伤病变后，血液中的总蛋白（TP）和白蛋白（ALB）仍处于正常状态，这可能与人体的稳态机制有关，如图2e和2f所示。",
        "page_idx": 5
    },
    {
        "type": "image",
        "img_path": "images/dc6fef6c8cc11ad58d755173186cdab27880675458728e42f1c9205b906333a6.jpg",
        "img_caption": [
            "Figure2．大鼠肝功结果 "
        ],
        "img_footnote": [],
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "3.3肝脏大体结果分析",
        "text_level": 1,
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "为对模型有直观的评估，我们直接观察处于肝癌-炎癌模型不同时期大鼠肝脏的表面观。如图3所示，3a、3b、3c、3d分别对应正常时期、肝炎时期、肝硬化时期、肝癌时期的大鼠肝脏。在健康时期，大鼠肝脏呈淡红色，无纹理，质地柔软到了肝炎时期肝脏颜色会较正常时期偏暗，并且质韧；发展到肝硬化时期，肝脏表面会有非常强的颗粒感，并出现黄白色斑点；当发展到肝癌时期时，肝脏可见暗红色肿块，并且肝脏表面弥漫灰白色结节。",
        "page_idx": 6
    },
    {
        "type": "image",
        "img_path": "images/b151ef338e060f3285063cc098ccaed19a5d9b0eeeeb7ee3ec9a12736f1476b0.jpg",
        "img_caption": [
            "Figure3．大鼠肝脏大体图"
        ],
        "img_footnote": [],
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "3.4病理切片结果分析",
        "text_level": 1,
        "page_idx": 6
    },
    {
        "type": "text",
        "text": "正常大鼠的结果如图4a所示，肝细胞索呈放射状排列，细胞质均质红染，核圆形居中，汇管区无炎细胞浸润。4周之后，大鼠切片结果如图4b，4c所示，间质及汇管区附近出现炎细胞浸润，呈轻度肝炎状态（4b），部分间质炎细胞浸润较多，呈中度肝炎（4c）。12周之后，间质区纤维组织增生，炎细胞浸润，假小叶生成，肝脏呈现结节性肝硬化症状（如图4d）。16-18周后，组织中可见较大面积的肿瘤组织，肿瘤细胞分化程度较高，排列较规则，少见核分裂现象，广泛可见静脉周围有结缔组织增生，伴有弥散的淋巴细胞浸润呈现肝癌早期症状（如图4e）。如图4f所示，发展到肝癌晚期之后，组织中可见较大面积的肿瘤组织，肿瘤细胞分化程度较低，排列欠规则，多见核分裂现象，可见弥散的肿瘤细胞凋亡，核碎裂或溶解。",
        "page_idx": 7
    },
    {
        "type": "image",
        "img_path": "images/33f78866cbe1496f98f303be0066ce75ced63ce650f91c06e7e0814ba801a937.jpg",
        "img_caption": [
            "Figure4.大鼠病理切片图"
        ],
        "img_footnote": [],
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "3.5尿液蛋白质组变化分析",
        "text_level": 1,
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "(1） 非监督聚类结果分析 ",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "为更好地判断大鼠肝癌-炎癌模型中尿蛋白组整体的变化情况，我们对各个大鼠各个时间点进行了非监督聚类，聚类结果如图5所示。其中，编号1-0代表1号大鼠注射二乙基亚硝胺之前，1-4代表1号大鼠注射4周药物之后，其余编号同理。其非监督聚类的结果显示，在最后肝癌时期的7只大鼠中，其中有6只分别是1，4，5，6，7，9号大鼠整体其尿蛋白变化情况受疾病影响较为明显；而3号大鼠则表现出明显的个体差异。这也提示我们，在疾病模型中，我们有必要注意个体差异带来的影响，我们的精准化医疗需要精准到每一个个体上。在受疾病影响比较明显的6只大鼠中，我们发现注射药物前的第0周，可以显著的聚集到一起与其他时间点分开；注射药物4-8周的时间点会相互交织在一起，这可能与这一时期大鼠处于肝炎时期，由于不同大鼠免疫力不同，所以肝炎的轻重进展也会不同，所以聚集到了一起；注射药物16周的时间点有的与注射药物12周的时间点聚在一起，有的与注射药物18周的时间点聚在一起，这可能也与肝癌-炎癌模型中个体不同导致的疾病进展快慢不同有关，有些大鼠在12周发展为肝硬化，有些则是16周，有些16周发展为肝癌，有些则是需要18周。总的来说，尿蛋白非监督聚类的结果虽然有相邻时间点的交错，但整体上把健康大鼠、肝炎大鼠、肝硬化大鼠、肝癌大鼠四个时期进行了区分，并且还提示了我们，部分个体会有较为明显的个体差异。",
        "page_idx": 7
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 8
    },
    {
        "type": "image",
        "img_path": "images/cf8f0345ca464c0b4c18cd7f1f97c9c022be3f5cbde766ab1ce9eec65b7b0df6.jpg",
        "img_caption": [
            "Figure5．尿蛋白非监督聚类结果图"
        ],
        "img_footnote": [],
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "(2） 差异蛋白和生物学通路分析",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "我们为了减少自身对照中生长发育的影响，对7只大鼠按照相邻时间点两两比较的方法寻找差异蛋白，7只大鼠第4、8、12、16、18周差异蛋白情况如表1所示，其具体uniprot信息如补充表1所示。我们将得到的差异蛋白通过IngenuityPathwayAnalysis软件进行分析，整理了不同样本不同时间点的IPA通路情况（如表2所示7只大鼠部分IPA通路，具体通路见补充表2）。",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "将7只大鼠共有的通路进行统计，最终得到32条IPA通路，其中多数都与肝癌-炎癌模型疾病的各阶段相关。在这32条通路中，有18条通路都与肝脏病变相关，其中主要包括三个方面：与肝脏损伤、炎症病变有关；与肿瘤的发生相关；肿瘤潜在的治疗靶点。有5条通路涉及到了肝脏的损伤、炎症、病变：外源代谢 PXR 信号通路[14】、α-肾上腺素能信号[15】LXR/RXR 激活[16】FXR/RXR 激活【16】铁稳态信号通路[17】。其中，根据查阅相关文献，外源代谢 PXR 信号通路和α-肾上腺素能信号与肝脏的损伤和炎症相关，LXR/RXR 激活和FXR/RXR 激活与肝脏本身的发育和代谢、炎症相关，铁稳态信号通路的出现则与肝纤维化的发生相关。并且这些通路大多在第4周和第8周就已富集到。有9条通路都被文献提到过与肿瘤的发生相关，其中包括：SPINK1胰腺癌途径【18】、NRF2介导的氧化应激反应【19】、谷胱甘肽介导的解毒作用[20】PXR/RXR 激活[21】、外源代谢 AHR信号通路【22]、急性期反应信号【23】糖异生I【24]补体系统【25】、网格蛋白介导的内吞信号【26】。它们都被提到与肿瘤甚至是肝癌的发生和发展相关。还有4条通路不仅与肿瘤的发生、生长有关，还被提及到可能作为潜在的肿瘤的治疗靶点，包括未折叠蛋白反应【27】、凝血系统[28】、凋亡信号[29】、糖酵解[【30】。这些潜在的靶点既有涉及肿瘤本身的生长和迁移，也有涉及癌细胞生长、代谢和调亡。",
        "page_idx": 8
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 9
    },
    {
        "type": "text",
        "text": "总的来说，我们本次的实验结果表明，我们的尿液蛋白质组可以发现肝癌-炎癌模型各个阶段的变化，这些变化所富集到的生物学过程也都被文献提及与肝炎、肝癌相关。并且由于生物体的个体差异，诱导肿瘤的炎癌模型会出现疾病进展快慢不同的个体差异现象。",
        "page_idx": 9
    },
    {
        "type": "table",
        "img_path": "images/28fe5f6de8a5c02b808ccb0b8140edc418fe5ea4fb55239e24e46bd216677409.jpg",
        "table_caption": [
            "Table1．7只大鼠所有时间点差异蛋白情况"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td colspan=\"5\">Tab1e1. 只大鼠所有时向点差异蛋白情况</td></tr><tr><td>大鼠编号</td><td>时间点</td><td>差异蛋白个数</td><td>上调</td><td>下调</td></tr><tr><td rowspan=\"5\">1</td><td>W4</td><td>154</td><td>81</td><td>73</td></tr><tr><td>W8</td><td>196</td><td>132</td><td>64</td></tr><tr><td>W12</td><td>156</td><td>53</td><td>103</td></tr><tr><td>W16</td><td>152</td><td>30</td><td>122</td></tr><tr><td>W18</td><td>108</td><td>61</td><td>47</td></tr><tr><td rowspan=\"5\">3</td><td>W4</td><td>91</td><td>55</td><td>36</td></tr><tr><td>W8</td><td>140</td><td>40</td><td>100</td></tr><tr><td>W12</td><td>86</td><td>55</td><td>31</td></tr><tr><td>W16</td><td>121</td><td>71</td><td>50</td></tr><tr><td>W18</td><td>179</td><td>96</td><td>83</td></tr><tr><td rowspan=\"4\">4</td><td>W4</td><td>157</td><td>65</td><td>91</td></tr><tr><td>W8</td><td>159</td><td>111</td><td>48</td></tr><tr><td>W12</td><td>137</td><td>33</td><td>104</td></tr><tr><td>W16</td><td>185</td><td>109</td><td>76</td></tr><tr><td rowspan=\"4\">5</td><td>W4</td><td>111</td><td>54</td><td>57</td></tr><tr><td>W8</td><td>104</td><td>45</td><td>59</td></tr><tr><td>W12</td><td>89</td><td>50</td><td>39</td></tr><tr><td>W16</td><td>161</td><td>82</td><td>79</td></tr><tr><td rowspan=\"5\">6</td><td>W4</td><td>196</td><td>104</td><td>92</td></tr><tr><td>W8</td><td>149</td><td>66</td><td>83</td></tr><tr><td>W12</td><td>90</td><td>49</td><td>41</td></tr><tr><td>W16</td><td>184</td><td>89</td><td>95</td></tr><tr><td>W18</td><td>142</td><td>71</td><td>71</td></tr><tr><td rowspan=\"4\">7</td><td>W4</td><td>123</td><td>63</td><td>60</td></tr><tr><td>W8</td><td>92</td><td>51</td><td>41</td></tr><tr><td>W12</td><td>108</td><td>49</td><td>59</td></tr><tr><td>W16</td><td>212</td><td>101</td><td>111</td></tr><tr><td rowspan=\"2\"></td><td>W4</td><td>100</td><td>38</td><td>62</td></tr><tr><td>W8</td><td>103</td><td>47</td><td>56</td></tr></table></body></html>",
        "page_idx": 9
    },
    {
        "type": "table",
        "img_path": "images/3fbcae67831efe0f729bb3fc43a93c5e0c5918d0d80cb245109e6b572d9ba429.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>9</td><td>W12</td><td>56</td><td>25</td><td>31</td></tr><tr><td></td><td>W16</td><td>178</td><td>114</td><td>64</td></tr><tr><td></td><td>W18</td><td>154</td><td>50</td><td>104</td></tr></table></body></html>",
        "page_idx": 10
    },
    {
        "type": "table",
        "img_path": "images/46fc8f2be30fe7455c53a6ec0a6a52a86b4d959a6d8b1cc95993aeea1435a8cc.jpg",
        "table_caption": [
            "Table2．7只大鼠IPA通路"
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td colspan=\"5\">Ingenuity Canonical Pathways</td></tr><tr><td>W4</td><td>W8</td><td>W12</td><td>W16</td><td>W18</td></tr><tr><td rowspan=\"3\">Unfolded protein response</td><td>SPINK1</td><td>LXR/RXR</td><td>Acute Phase Response</td><td>Glioma Invasivenes</td></tr><tr><td>Pancreatic Cancer</td><td>Activation</td><td>Signaling</td><td>s Signaling</td></tr><tr><td>Pathway Role of IL-17A Acute Phase in Psoriasis Response</td><td>FXR/RXR Activation</td><td>Tumoricidal Function of</td><td>Macropinocy tosis</td></tr><tr><td>Glucocorticoid Receptor</td><td>Signaling Gap Junction</td><td>Acute Phase Response</td><td>Hepatic Natural Killer Cells Cytotoxic T Lymphocyte-</td><td>Signaling Actin Cytoskeleto</td></tr><tr><td>Signaling SPINK1 Pancreatic</td><td>Signaling Superpathwa yof</td><td>Signaling Complement System</td><td>mediated Apoptosis of Target Cells Iron homeostasis</td><td>n Signaling PXR/RXR</td></tr><tr><td>Cancer Pathway NRF2-Mediated Oxidative</td><td>Methionine Degradation Glutathione Biosynthesi S</td><td>Triacylglycerol Degradation</td><td>signaling pathway Mitochondrial Dysfunction</td><td>Activation Germ Cell- Sertoli</td></tr><tr><td>Stress Response Parkinson' s Signaling</td><td>Remodeling of Epithelial</td><td>Iron homeostasis signaling pathway</td><td>Lymphotoxin βReceptor</td><td>Cell Junction Signaling PEDF Signaling</td></tr><tr><td>Mitochondrial Dysfunction</td><td>Adherens Junctions Germ Cel1- Sertoli Cell</td><td>Gluconeogenesis I</td><td>CD27 Signaling in Lymphocytes</td><td>Xenobiotic Metabolism AHR</td></tr><tr><td>Sirtuin</td><td>Junction Signaling NRF2-</td><td></td><td>Induction of</td><td>Signaling Pathway</td></tr><tr><td>Signaling</td><td>Mediated</td><td>Glycolysis I</td><td>Apoptosis by</td><td>Leukocyte Extravasati</td></tr><tr><td>Pathway</td><td>Oxidative</td><td></td><td>HIV1</td><td>on</td></tr></table></body></html>",
        "page_idx": 10
    },
    {
        "type": "table",
        "img_path": "images/8a43ffdf57dbc74258aa1b21e482a454d581b6c6dc0e42dec4ff2003da67f78c.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td colspan=\"3\">Stress</td><td rowspan=\"2\">Pyruvate</td><td rowspan=\"2\">Signaling LPS-</td></tr><tr><td>Huntington' s</td><td>Response ERK5</td><td>2-amino-3- carboxymuconate</td></tr><tr><td>Disease Signaling</td><td>Signaling</td><td>Semialdehyde Degradation to Glutaryl-CoA</td><td>Fermentation to Lactate</td><td>stimulated MAPK Signaling</td></tr><tr><td>Glutathione Redox Reactions I</td><td>Ketolysis</td><td>Antiproliferative Role of TOB in T Cell Signaling</td><td>Eumelanin Biosynthesis</td><td>Actin Nucleation by ARP-WASP Complex</td></tr><tr><td>NRF2-Mediated Oxidative Stress Response</td><td>Acute Phase Response Signaling</td><td>SPINK1 Pancreatic Cancer Pathway</td><td>SPINK1 Pancreatic Cancer Pathway</td><td>Acute Phase Response Signaling</td></tr><tr><td>Glutathione Redox Reactions I</td><td>LXR/RXR Activation</td><td>Oxidative Phosphorylation</td><td>Oxidative Phosphorylati on</td><td>LXR/RXR Activation</td></tr><tr><td>LXR/RXR Activation</td><td>FXR/RXR Activation</td><td>Huntington' s Disease Signaling</td><td>Huntington' s Disease Signaling</td><td>FXR/RXR Activation</td></tr><tr><td>Glutathione mediated Detoxification</td><td>Coagulation System</td><td>Retinol Biosynthesis</td><td>Retinol Biosynthesis</td><td>Coagulation System</td></tr><tr><td>Inhibition of Matrix Metalloproteas</td><td>Complement System</td><td>G Protein Signaling Mediated by Tubby</td><td>G Protein Signaling Mediated by</td><td>Intrinsic Prothrombin Activation</td></tr><tr><td>es SPINK1 Pancreatic Cancer Pathway</td><td>Caveolar mediated Endocytosis</td><td>Apelin Muscle Signaling Pathway</td><td>Tubby Apelin Muscle Signaling Pathway</td><td>Pathway Iron homeostasis signaling</td></tr><tr><td>Xenobiotic Metabolism PXR Signaling</td><td>Signaling Clathrin- mediated Endocytosis</td><td>Triacylglycerol Degradation</td><td>Triacylglycer ol Degradation</td><td>pathway Complement System</td></tr><tr><td>Pathway PXR/RXR Activation</td><td>Signaling Atheroscler osis Signaling</td><td>Lactose Degradation III</td><td>Lactose Degradation III</td><td>Extrinsic Prothrombin Activation</td></tr><tr><td>Ceramide Degradation</td><td>IL-12 Signaling and</td><td>Eicosanoid Signaling</td><td>Eicosanoid Signaling</td><td>Pathway Pyruvate Fermentatio nto</td></tr></table></body></html>",
        "page_idx": 11
    },
    {
        "type": "table",
        "img_path": "images/daed7536c3eb85c6540d1a218c364fc3936fff60b5c4a19377e48a4f3448b245.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td colspan=\"3\">Production in</td><td colspan=\"3\">Lactate</td></tr><tr><td>IL-15 Signaling</td><td>Macrophages Iron homeostasis</td><td>Endothelin-1 Signaling</td><td>Endothelin-1 Signaling</td><td>Gluconeogen esis I</td></tr><tr><td>NRF2-Mediated Oxidative</td><td>signaling pathway Ferroptosis Signaling</td><td>Mitochondrial Dysfunction</td><td>SPINK1 Pancreatic</td><td></td></tr><tr><td>Stress Response Apelin Adipocyte</td><td>Pathway Complement System</td><td>TCA Cycle II (Eukaryotic)</td><td>Cancer Pathway Coagulation System</td><td></td></tr><tr><td>Signaling Pathway PXR/RXR</td><td>Apoptosis</td><td>Oxidative</td><td>LXR/RXR</td><td></td></tr><tr><td>Activation Xenobiotic Metabolism PXR</td><td>Signaling Acute Phase Response</td><td>Phosphorylation Gluconeogenesis I</td><td>Activation Acute Phase Response</td><td></td></tr><tr><td>Signaling Pathway Acute Phase Response Signaling</td><td>Signaling LXR/RXR Activation</td><td>GlycolysisI</td><td>Signaling Extrinsic Prothrombin Activation</td><td></td></tr><tr><td>Unfolded protein response</td><td>Glutamine Biosynthesi sI</td><td>Sirtuin Signaling Pathway</td><td>Pathway Chondroitin Sulfate Degradation (Metazoa)</td><td></td></tr><tr><td>Glutathione Redox Reactions I</td><td>L-cysteine Degradation II</td><td>Choline Degradation I</td><td>Airway Pathology in Chronic Obstructive Pulmonary</td><td></td></tr><tr><td>Methylthioprop ionate Biosynthesis</td><td>Glutaryl- CoA Degradation</td><td>Xanthine and Xanthosine</td><td>Disease Atheroscleros is Signaling</td><td></td></tr><tr><td>Glutathione- mediated</td><td>Phagosome Maturation</td><td>Salvage SPINK1 Pancreatic Cancer Pathway</td><td>Superoxide Radicals</td><td></td></tr><tr><td>Detoxification Intrinsic Prothrombin</td><td>Necroptosis Signaling</td><td>Triacylglycerol Degradation</td><td>Degradation Complement System</td><td></td></tr></table></body></html>",
        "page_idx": 12
    },
    {
        "type": "table",
        "img_path": "images/4ff07c4438c062347e5a73ea93e922d46ecf59183cc5fceb51c6bca6416f33dd.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Activation Pathway</td><td>Pathway</td><td></td><td></td></tr><tr><td>NRF2-Mediated Oxidative Stress</td><td>Acute Phase Response Signaling</td><td>Coagulation System</td><td>Gluconeogenes isI</td></tr><tr><td>Response Gap Junction Signaling</td><td>LXR/RXR Activation</td><td>Acute Phase Response Signaling</td><td>Glycolysis I</td></tr><tr><td>Axonal Guidance Signaling</td><td>FXR/RXR Activation</td><td>Intrinsic Prothrombin Activation Pathway</td><td>Mitochondrial Dysfunction</td></tr><tr><td>Circadian Rhythm Signaling</td><td>SPINK1 Pancreatic Cancer Pathway</td><td>Extrinsic Prothrombin Activation Pathway</td><td>LPS/IL-1 Mediated Inhibition of RXR Function</td></tr><tr><td>Apelin Adipocyte Signaling Pathway</td><td>Methylglyox al Degradation I</td><td>LXR/RXR Activation</td><td>Acute Phase Response Signaling</td></tr><tr><td>Gluconeogenesi sI</td><td>Lysine Degradation II</td><td>SPINK1 Pancreatic Cancer Pathway</td><td>LXR/RXR Activation</td></tr><tr><td>Glycolysis I Glutathione</td><td>Lysine Degradation V TR/RXR</td><td>FXR/RXR Activation Role of Tissue</td><td>Glutathione Redox Reactions I Aspartate</td></tr><tr><td>Redox Reactions I Sorbitol Degradation I</td><td>Activation Airway Pathology</td><td>Factor in Cancer GP6 Signaling Pathway</td><td>Degradation II Xenobiotic Metabolism</td></tr><tr><td>Glutathione-</td><td>in Chronic Obstructive Pulmonary Disease Atheroscler</td><td>Complement System</td><td>AHR Signaling Pathway Superoxide</td></tr><tr><td>mediated Detoxification SPINK1 Pancreatic Cancer Pathway Superoxide</td><td>osis Signaling Glutathione Biosynthesi S Y-glutamyl</td><td>NRF2-Mediated Oxidative Stress Response</td><td>Radicals Degradation Acute Phase Glycolysis Response I Signaling</td></tr></table></body></html>",
        "page_idx": 13
    },
    {
        "type": "table",
        "img_path": "images/d7f3f71b5eaf66ccab9be623f2944acedd24f4cd5014409787801b58ff502c8a.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Radicals Degradation</td><td>Cycle</td><td>Activation</td><td>Activation</td><td>esis I</td></tr><tr><td>Intrinsic Prothrombin Activation Pathway</td><td>Glycolysis I</td><td>Xenobiotic Metabolism PXR Signaling Pathway</td><td>FXR/RXR Activation</td><td>Pyruvate Fermentatio nto Lactate</td></tr><tr><td>Extrinsic Prothrombin Activation Pathway</td><td>Gluconeogen esis I</td><td>Apelin Adipocyte Signaling Pathway</td><td>Y-glutamyl Cycle</td><td>NRF2- Mediated Oxidative Stress Response</td></tr><tr><td>NRF2-Mediated Oxidative Stress Response</td><td>Glutamine Biosynthesi sI</td><td>Glutathione Redox Reactions I</td><td>Iron homeostasis signaling pathway</td><td>PXR/RXR Activation</td></tr><tr><td>Mitochondrial Dysfunction</td><td>Complement System</td><td>Neuroprotective Role of THOP1 in Alzheimer's Disease</td><td>Glutathione Biosynthesis</td><td>Xenobiotic Metabolism AHR Signaling Pathway</td></tr><tr><td>NAD Salvage Pathway II Amyotrophic</td><td>LXR/RXR Activation NRF2-</td><td>Methylthiopropion ate Biosynthesis MIF-mediated</td><td>Atheroscleros is Signaling Coagulation</td><td>Unfolded protein response Glutathione</td></tr><tr><td>Lateral Sclerosis Signaling</td><td>Mediated Oxidative Stress Response</td><td>Glucocorticoid Regulation</td><td>System</td><td>Redox Reactions I</td></tr><tr><td>Glutathione Redox Reactions I Senescence</td><td>FXR/RXR Activation Ferroptosis</td><td>Glutathione- mediated Detoxification Huntington's</td><td>Complement System Hepatic</td><td>HIF1 α Signaling Glucocortic</td></tr><tr><td>Pathway Coronavirus</td><td>Signaling Pathway SPINK1</td><td>Disease Signaling Hepatic Fibrosis</td><td>Fibrosis / Hepatic Stellate Cell Activation</td><td>oid Receptor Signaling</td></tr><tr><td>Replication Pathway Coronavirus Pathogenesis Pathway</td><td>Pancreatic Cancer Pathway Retinol Biosynthesi S</td><td>Signaling Pathway Apelin Adipocyte Signaling Pathway</td><td>Acute Phase Response Signaling LXR/RXR Activation</td><td></td></tr></table></body></html>",
        "page_idx": 14
    },
    {
        "type": "table",
        "img_path": "images/74ffe3436475c4aa454a0653d7fed4a78c864d6caae75b7a85f637804db5bdf2.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Axonal Guidance Signaling</td><td>Triacylglyc erol Degradation</td><td>Osteoarthritis Pathway</td><td>FXR/RXR Activation</td></tr><tr><td>Neuroprotectiv e Role of THOP1 in Alzheimer' s</td><td>Pulmonary Healing Signaling Pathway</td><td>LXR/RXR Activation</td><td>Coagulation System</td></tr><tr><td>NRF2-mediated Oxidative Stress Response Methylglyoxal Degradation I</td><td>TCA Cycle II (Eukaryotic ） L-cysteine Degradation II</td><td>Endocannabinoid Developing Neuron Pathway CCR3 Signaling in Eosinophils</td><td>Complement System Iron homeostasis</td></tr><tr><td>Hypusine Biosynthesis</td><td>Superpathwa yof Methionine</td><td>Colorectal Cancer Metastasis Signaling</td><td>pathway Tryptophan Degradation X (Mammalian, via</td></tr><tr><td>SPINK1 Pancreatic Cancer Pathway</td><td>Coronavirus Replication Pathway</td><td>Phagosome Maturation</td><td>Gluconeogenes isI</td></tr><tr><td>Phosphate Pathway (Oxidative Branch)</td><td>Signaling Pathway</td><td>Apoptosis Signaling</td><td>Degradation II</td></tr><tr><td>Arginine Biosynthesis IV</td><td>Sirtuin Signaling Pathway</td><td>Axonal Guidance Signaling</td><td>Noradrenaline and Adrenaline Degradation</td></tr><tr><td>Pancreatic Cancer Pathway</td><td>Apelin Adipocyte Signaling Pathway</td><td>(Eukaryotic)</td><td>Response Signaling Psoriasis</td></tr><tr><td>Glucocorticoid Receptor Signaling</td><td>G Protein Signaling Mediated by Tubby</td><td>Death Receptor Signaling</td><td>LXR/RXR HIF1α Activation Signaling</td></tr><tr><td>Germ Cel1- Sertoli Cell</td><td>Androgen Signaling</td><td>2-ketoglutarate Dehydrogenase</td><td>FXR/RXR Activation</td></tr></table></body></html>",
        "page_idx": 15
    },
    {
        "type": "table",
        "img_path": "images/49e2d615558298c4e0c4156d564ba2bb5cbc14980efe25857b058ebdf640409a.jpg",
        "table_caption": [],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td colspan=\"2\">Junction Signaling</td><td colspan=\"3\">Complex</td></tr><tr><td>Pulmonary Healing Signaling Pathway</td><td>IL-1 Signaling</td><td>Branched-chain α -keto acid Dehydrogenase Complex</td><td>Coagulation System</td><td>Glycolysis I</td></tr><tr><td>Sertoli Cell- Sertoli Cell Junction Signaling</td><td>Apelin Muscle Signaling Pathway</td><td>Apoptosis Signaling</td><td>Intrinsic Prothrombin Activation Pathway</td><td>LXR/RXR Activation</td></tr><tr><td>Remodeling of Epithelial Adherens Junctions</td><td>Axonal Guidance Signaling</td><td>Creatine- phosphate Biosynthesis</td><td>Complement System</td><td>Role of PKR in Interferon Induction and Antiviral Response</td></tr><tr><td>Sirtuin Signaling Pathway</td><td>α- Adrenergic Signaling</td><td>2-oxobutanoate Degradation I</td><td>Extrinsic Prothrombin Activation Pathway</td><td>Phagosome Maturation</td></tr><tr><td>Sucrose Degradation V (Mammalian)</td><td>Oxytocin Signaling Pathway</td><td>Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase Complex)</td><td>Iron homeostasis signaling pathway</td><td>Methylglyox al Degradation I</td></tr><tr><td>Chondroitin Sulfate Degradation (Metazoa)</td><td>Gas Signaling</td><td>Glycine Cleavage Complex</td><td>Osteoarthriti s Pathway</td><td>Hypusine Biosynthesi S</td></tr><tr><td>Dermatan Sulfate Degradation (Metazoa)</td><td>G Beta Gamma Signaling</td><td>Aspartate Degradation II</td><td>Role of Tissue Factor in Cancer</td><td>Pyruvate Fermentatio n to Lactate</td></tr></table></body></html>",
        "page_idx": 16
    },
    {
        "type": "text",
        "text": "参考文献：",
        "text_level": 1,
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "[1]YouHe Gao.Urine—an untapped goldmine forbiomarker discovery?[J]. Science China Life Sciences,2013,56(12).   \n[2]Thongboonkerd V, McLeish K R,Arthur JM,et al. Proteomic analysis of normal human urinary proteins isolated acetone precipitation or ultracentrifugation. Kidney Int, 20o2, 62: 1461-1469.   \n[3] Yuhang Huan,Weiwei Qin,Youhe Gao.Factors to consider in the verification of urinary biomarkers[J].Science China(Life Sciences),2018,61(10):1283-1290.   \n[4] Tomasz PRadon1,Nathalie JMassat.Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma[J]. Clin Cancer Res.2015 August 1; 21(15): 3512-3521.   \n[5] Virginia Urquidil，Mandy Netherton.Urinary mRNA biomarker panel for the detection of urothelial carcinoma[J]. Oncotarget,2016. Vol.7, No. 25.   \n[6] Youhe Gao.Roadmap to the Urine Biomarker Era[A].国家外国专家局国外人才资源总库大连人才分库、百 奥泰国际会议（大连）有限公司.2015年第一届国际泌尿医学会议会刊[C].国家外国专家局国外人才资源总 库大连人才分库、百奥泰国际会议（大连）有限公司:百奥泰国际会议(大连)有限公司,2015:1.   \n[7]刘煌,刘静.肝癌动物模型的研究进展[J].世界华人消化杂志,2011,19(12):1275-1278.   \n[8] Dr.D.Max Parkin MD,Mr.Freddie Bray,Mr.J.Ferlay,Dr.Paola Pisani PhD.Global Cancer Statistics,2002[J]. CA: A Cancer Journal for Clinicians,20o5,55(2).   \n[9] Philippa Newell,Augusto Villanueva,Scott L.Friedman,Kazuhiko Koike,Josep M.Llovet.Experimental models of hepatocellular carcinoma[J]. Journal of Hepatology,2oo8,48(5).   \n[10] Wisniewski, JR.,et al.,， Universal sample preparation method for proteome analysis.Nat Methods, 2009. 6(5): p. 359-62.   \n[11] Armitage,E.G.,et al.,，Mising value imputation strategies for metabolomics data.Electrophoresis,2015. 36(24): p. 3050-60.   \n[12] Wang,S.,et al.,NAguideR: performing and prioritizing missing value imputations for consistent bottom-up proteomic analyses. Nucleic Acids Res, 2020.48(14): p. e83.   \n[13] Huang da, W.,B.T. Sherman,and R.A.Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc,2009.4(1): p. 44- 57.   \n[14] Mutual repression between steroid and xenobiotic receptor and NF-kB signaling pathways links xenobiotic metabolism and inflammation[J]. The Journal of Clinical Investigation, 20o6,116(8):   \n[15]Lin Jung-Chun,Peng Yi-Jen,Wang Shih-Yu,Lai Mei-Ju,Young Ton-Ho,Salter Donald M,Lee Herng-Sheng. Sympathetic Nervous System Control of Carbon Tetrachloride-Induced Oxidative Stress in Liver through α- Adrenergic Signaling.[J]. Oxidative medicine and cellular longevity, 2016,2016:   \n[16] Yin and Yang Regulation of Liver X Receptor $\\mathfrak { a }$ Signaling Control of Cholesterol Metabolism by Poly(ADPribose) polymerase 1.[J]. International journal of biological sciences,202o,16(15):   \n[17] Changying Li,Yingying Liu,Zheng Dong,Ming Xu,Ming Gao,Min Cong,Sijin Liu. TCDD promotes liver fibrosisthroughdisorderingsystemicandhepaticironhomeostasis[J].JournalofHazardous Materials,2020,395(prepublish):   \n[18] 赵娜,郑洋,陈丽丽,荆东辉,王华庆.SPINK1作为肿瘤标志物的临床价值与应用[J].国际肿瘤学杂 志,2020,47(07):414-418.   \n[19]Liu Qian,Zhang Hao,Smeester Lisa,ZouFeiKesic Mat,Jaspers Ilona,Pi JingboFry Rebecca C.The NRF2- mediated oxidative stressresponse pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.[J]. BMC medical genomics,2010,3(1):   \n[20] Ding Yiming,Dai Yujie,Wu Mengqi,Li Linlin. Glutathione-mediated nanomedicines for cancer diagnosis and therapy[J]. Chemical Engineering Journal,2021,426:   \n[21]郭恩爽.HBx在HBV 诱发的肝细胞癌中干预PXR/RXRα对CYP3A4表达调控的机制研究[D].南方医科 大学,2014.   \n[22] Dietrich C, Kaina B.The aryl hydrocarbon receptor(AhR) in the regulation of cell-cellcontact and tumor growth[J]. Pergamon Press, 2010.   \n[23]Rania Dayoub,Leonhard Buerger,Sara Ibrahim,Michael Melter,Thomas S.Weis.Augmenter of liver regeneration (ALR） exhibits a dual signaling impact on hepatic acute-phase response[J]. Experimental and Molecular Pathology,2017,102(3):   \n[24]Roh M S,Ekman L,Jeevanandam M,Brennan MF. Gluconeogenesis in tumor-influenced hepatocytes.[J]. Surgery,1984,96(2):   \n[25]张玲玲,徐蔚然,梁军.补体活化与肿瘤免疫关系的新进展[J].中华检验医学杂志,2017,40(09):664-666. [26] Wang Xiaowei, Qiu Yuhan,Wang Mengyan, Zhang Conghui, Zhang Tianshu, Zhou Huimin,Zhao Wenxia, Zhao Wuli,， Xia Guimin, Shao Rongguang. Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy.[J]. International journal of nanomedicine, 2020,15:   \n[27] Obacz J,AvrilT,Camila Rubio-Patio,et al.Regulation of tumor-stroma interactions bythe unfolded protein response[J]. The FEBS Journal,2019,286(2).   \n[28] Magnus N，D'Asti E,Meehan B ，et al. Oncogenes and the coagulation system - Forces that modulate dormant and aggressive states in cancer[J]. Thrombosis Research,2014,133 Suppl 2(Suppl):S1-9.   \n[29] Fulda Simone, Debatin Klaus-Michael. Apoptosis signaling in tumor therapy[J]. Annals of the New York Academy of Sciences,2004,1028:   \n[30] Ganapathy-Kanniappan Shanmugasundaram. Targeting tumor glycolysis by a mitotropic agent.[J]. Expert opinion on therapeutic targets,2016,20(1): 作者贡献声明： 王云龙、高友鹤：提出研究思路，设计研究方案;   \n王云龙：进行实验；   \n王云龙：分析数据；   \n王云龙：论文起草；   \n高友鹤：论文最终版本修订。 ",
        "page_idx": 17
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 18
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 19
    }
]